Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Article Details

Citation

Copy to clipboard

Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5.

PubMed ID

21054754 [ View in PubMed

]

Abstract

OBJECTIVE: * To evaluate the impact and distribution of a single phosphodiesterase type 5 inhibitor (PDE5 I) dose (udenafil or tadalafil) in prostate tissue and plasma in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: * Thirty BPH patients complaining of erectile dysfunction along with moderate-to-severe lower urinary tract symptoms (LUTS) who underwent transurethral resection of the prostate (TURP) were enrolled in the present study. * The patients were randomly divided into the three groups: group 1, TURP without PDE5 Is; group 2, 200 mg of udenafil given 1 h before TURP; and group 3, 20 mg of tadalafil given 1 h before TURP. * We evaluated the concentrations of PDE5-I, cAMP and cGMP in prostate tissues and plasma, and calculated the prostate tissue-to-plasma (T/P) ratio. RESULTS: * The concentration of udenafil in prostate tissue and plasma was 2028.6 +/- 360.8 ng/g and 463.7 +/- 39.1 ng/mL, respectively, and the resulting T/P ratio was 4.4. The tadalafil concentration in prostate tissue and plasma was 385.7 +/- 83.8 ng/g and 305.8 +/- 41.1 ng/mL, respectively, and the T/P ratio was 1.3. * Udenafil and tadalafil significantly increased the cAMP and cGMP levels in plasma and prostate tissues. CONCLUSIONS: * Udenafil and tadalafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. * These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Udenafil	cGMP-specific 3',5'-cyclic phosphodiesterase	Protein	Humans	Yes	Inhibitor	Details

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Tadalafil	Approved Investigational	CAMP	increased	Tadalafil increases the level of CAMP in the blood
Tadalafil	Approved Investigational	CGMP	increased	Tadalafil increases the level of CGMP in the blood